Gutenberg Technology Launches AI Course Builder, Transforming U.S. Digital Learning Landscape

BOSTON, June 10, 2025 /PRNewswire/ -- Amid rapid technological transformation across the global workforce, Gutenberg Technology (GT) — a French-American SaaS innovator with offices in Boston and headquarters in Paris — has unveiled its groundbreaking AI Course Builder, a powerful new addition to its award-winning Learning Content Management System (LCMS). Built to think like a Learning Designer and fundamentally rooted in proven learning science principles, GT's AI Course Builder is the first solution of its kind to harness artificial intelligence to accelerate and elevate digital course creation. By reducing development time by up to 80% while enhancing instructional quality, it meets the growing demand for agile, personalized learning across corporate training teams, eLearning providers, educational publishers, and academic institutions.
Bridging the U.S. Skills Gap in a Transforming Economy
The U.S. labor market is undergoing a significant transformation. According to the World Economic Forum's Future of Jobs Report 2025, employers anticipate that 39% of core skills required across jobs will change by 2030. Additionally, 41% of employers plan to reduce their workforce due to automation, while 70% intend to hire new talent with AI-related skills.
Dario Amodei, CEO of AI lab Anthropic, warns that AI could eliminate up to 50% of entry-level white-collar jobs within five years, potentially raising U.S. unemployment to 20% by 2030. These projections underscore the critical need for rapid upskilling and reskilling initiatives.
While the imperative for rapid upskilling is clear, forward-thinking organizations recognize it as more than just a defensive strategy. By empowering employees with timely, relevant skills, companies can transform potential disruptions into opportunities for innovation and growth. This proactive approach not only enhances productivity but also fosters a culture where employees are equipped to focus on high-value tasks, driving the organization toward greater efficiency and competitiveness.
GT's AI Course Builder drastically streamlines the digital content creation process by converting existing materials, such as Word documents, PowerPoint slides, PDFs, videos, audio files, and eBooks, into structured, interactive eLearning modules in minutes, not weeks or months. Learning Designers and Subject Matter Experts (SMEs) can then fine-tune the AI-generated content, allowing them to shift their focus from time-consuming production tasks to enhancing the learner experience. The result is faster course development, higher quality learning, and more time spent on what truly matters: engagement and impact.
Empowering Learning Designers and Learning Organizations
By applying configurable pedagogical templates to source content, the AI Course Builder automates much of the initial work required to build a course so Learning Designers and SMEs can concentrate on strategic, high-value learning activities such as curriculum innovation and learner engagement.
Gjergj Demiraj, CEO of Gutenberg Technology, commented:
"Organizations today— whether corporate eLearning providers, educational publishers, or academic institutions—face unprecedented pressure to rapidly deliver engaging and impactful digital learning experiences. The AI Course Builder is the latest innovation in our expanding suite of AI-powered tools designed to help our customers accelerate course development without compromising quality. What excites us most isn't just what this tool can do today, but what it unlocks for tomorrow. With the addition of agentic AI capabilities, we're laying the foundation for self-optimizing learning systems—helping organizations shift from manual production to intelligent orchestration, and ultimately transforming how knowledge is created, delivered, and evolved."
Strategic Expansion in the U.S. Market
GT has established a strong presence in both the U.S. and European markets with its award-winning Learning Content Management System, trusted by global leaders such as Cengage Learning, National Geographic Learning, Vista Higher Learning, and CompTIA. Following a successful soft launch of the AI Course Builder in France, where several major eLearning providers adopted the platform to deliver high-volume legal, compliance, and professional development training, GT is now expanding availability to the U.S. and other international markets. To support this global rollout, GT is enhancing the platform to serve additional high-demand content areas, including Cybersecurity, Project Management, and Nursing.
Gutenberg Technology's AI Course Builder was recently awarded the prestigious 2025 EdTech Cool Tool Award for Best Authoring Tools Solution, recognizing its breakthrough innovation in instructional design. This honor underscores the platform's ability to rapidly produce dynamic, engaging, and standards-aligned eLearning experiences powered by AI and built for today's fast-paced learning demands.
About Gutenberg Technology (GT)
Founded in 2012, Gutenberg Technology (GT) is a Franco-American SaaS company revolutionizing how educational and training content is created, managed, and delivered at scale. With headquarters in Boston and offices in Paris, GT provides an end-to-end platform combining its award-winning AI Course Builder and intelligent Content Management System (AI CMS) to accelerate the production of engaging, interactive learning experiences.
Trusted by more than 7,000 content creators worldwide, GT's platform has powered the creation of over 230,000 learning assets, reaching 7+ million learners across higher education, corporate training, and digital learning providers.
At the heart of GT's vision is a bold ambition: to industrialize course design through artificial intelligence—without compromising on pedagogical quality or human creativity. With deep roots in the U.S. and a rapidly growing global presence, GT is the partner of choice for publishers, universities, and training organizations reimagining the future of learning.
ContactKatie Sutton
Katie@gutenberg-technology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/gutenberg-technology-launches-ai-course-builder-transforming-us-digital-learning-landscape-302477839.html
SOURCE Gutenberg Technology

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

an hour ago

• Business Insider

Women are getting wealthier — and they don't invest the same way as men

Women are becoming richer, and they're changing the face of wealth. According to a report by McKinsey published last month, women control about a third of all retail financial assets in the US and the European Union. By 2030, that proportion is expected to rise to between 40% to 45%, wrote Cristina Catania, global co-convener and European lead for the risk and resilience practice, and Jill Zucker, senior partner and co-leader of McKinsey's global growth transformation service line. The report is based on a survey of about 13,000 American and European investors, nearly half of whom were female financial decision makers. It found that between 2018 and 2023, global wealth rose by 43%, but jumped by 51% for women. Women's expanding control of assets is being driven by a combination of factors, including a continuing decline in marriage rates, the ongoing boost in women's average earnings, demographic trends like longer life expectancies, and a broad shift in attitudes about women managing their own finances. Risk doesn't equal reward As women become wealthier through investing, it's becoming clearer that they don't approach it the same way as men. "Women are much more risk-aware," Anna-Sophie Hartvigsen, cofounder of financial education and investment platform Female Invest, told Business Insider. "I would like to call it much more realistic in their own ability to invest." She said women are less likely than men to invest emotionally. "On average, men trade a lot more often than women because they believe they can beat the market or they read something in the news, and they get pumped up or afraid, and then they invest based on that," Hartvigsen said. Female investors, in her view, tend to be more calm, more realistic, and better at assessing risk. However, Katie Geery, an advisor at Rise Private Wealth Management, says being more cautious can also hold women back by leading them to miss out on opportunities to build wealth. "It is important to work with a trusted financial advisor who understands your risk tolerance and can walk you through making well-educated investment decisions based on your long-term goals," she told BI. Returns aren't everything The aims of investing also sometimes differ between men and women. "Women prefer to invest toward achieving specific goals rather than chasing the highest returns," said Avanti Shetye, financial planner at Wealthwyzr. Geery said female investors tend to be more focused on philanthropy and gifting. They often consider their values when buying stock and want their purchases to help make a better impact on the world. "Women often seek financial advisors who are empathetic and take the time to get to know them on a more personal level to gain a deeper understanding of their goals and values," she said. On Female Invest, Hartvigsen said the principles its members care about the most include climate, especially a firm's carbon footprint, and diversity in leadership, in terms of a board having a good gender balance. Start investing early For Shetye, it's important to start investing early. "Women tend to be primary caregivers for children or aging parents and often take unpaid time off," she said. "Not only that, women statistically live longer than men, which implies that women would need to invest as much as they can as early as possible so that their portfolios last them through retirement." Hartvigsen said long-term financial planning is vital: "When you do that, it doesn't matter what happens today." Both agree that this plan should be grounded in expert advice. "Working with a financial planner whose planning process is rooted in financial education can help provide comfort and security to stay consistent even in the roughest of markets," Shetye said. But she also believes that practice is more important than perfection. "You are never going to know everything there is to know about investing," Shetye said. "The key is consistency, and time will do the heavy lifting." Hartvigsen advises her clients to invest monthly on the same day and to diversify their investments. "If you do that, historically, it has been near impossible not to make money in the long run."

Los Angeles Times

an hour ago

• Los Angeles Times

How Iran could retaliate after the U.S. strikes on its nuclear program

DUBAI — Iran has spent decades building multi-tiered military capabilities at home and across the region that were at least partly aimed at deterring the United States from attacking it. By entering Israel's war, the U.S. may have removed the last rationale for holding them in reserve. That could mean a wave of attacks on U.S. forces in the Middle East, an attempt to close a key bottleneck for global oil supplies, or a dash to develop a nuclear weapon with what remains of Iran's disputed program after American strikes on three key sites. A decision to retaliate against the U.S. and its regional allies would give Iran a far larger target bank and one that is much closer than Israel, allowing it to potentially use its missiles and drones to greater effect. The U.S. and Israel have far superior capabilities, but those haven't always proved decisive in America's recent history of military interventions in the region. Ever since Israel started the war with a surprise bombardment of Iran's military and nuclear sites June 13, Iranian officials from the supreme leader on down have warned the U.S. to stay out, saying that direct American involvement would have dire consequences for the entire region. It should soon be clear whether those were merely threats or a grim forecast. Here's a look at what Iran's next move might be. The Strait of Hormuz is the narrow mouth of the Persian Gulf, through which some 20% of all oil traded globally passes, and at its narrowest point it is just 21 miles wide. Any disruption there could send oil prices soaring worldwide and hit American pocketbooks. Iran boasts a fleet of fast-attack boats and thousands of naval mines that could potentially make the strait impassable, at least for a time. It could also fire missiles from its long Persian Gulf shore, as its allies, Yemen's Houthi rebels, have done in the Red Sea. The U.S., with its 5th Fleet stationed in nearby Bahrain, has long pledged to uphold freedom of navigation in the strait and would respond with far superior forces. But even a relatively brief battle could paralyze shipping traffic and spook investors, causing oil prices to spike and generating international pressure for a ceasefire. The U.S. has tens of thousands of troops stationed in the region, including at permanent bases in Kuwait, Bahrain, Qatar and the United Arab Emirates — Arab Gulf countries just across the Persian Gulf from Iran — and much closer than Israel. Those bases have the same kinds of sophisticated air defenses as Israel's, but would have much less warning time before waves of missiles or swarms of armed drones. And even Israel, which is several hundred miles farther away, has been unable to stop all of the incoming fire. Iran could also choose to attack key oil and gas facilities in those countries with the goal of exacting a higher price for U.S. involvement in the war. A drone attack on two major oil sites in Saudi Arabia in 2019 — claimed by the Houthis but widely blamed on Iran — briefly cut the kingdom's oil production in half. Iran's so-called 'Axis of Resistance' — a network of militant groups across the Middle East — is a shadow of what it was before the war ignited by Hamas' Oct. 7, 2023, attack on Israel out of the Gaza Strip, but it still has some formidable capabilities. Israel's 20-month war in Gaza has severely diminished the Palestinian Hamas and Islamic Jihad groups, and Israel decimated Lebanon's Hezbollah last fall, killing most of its top leadership and devastating much of southern Lebanon, making its involvement unlikely. But Iran could still call on the Houthis, who had threatened to resume their attacks in the Red Sea if the U.S. entered the war, and allied militias in Iraq. Both have drone and missile capabilities that would allow them to target the United States and its allies. Iran could also seek to respond through militant attacks farther afield, as it is widely accused of doing in the 1990s with an attack on a Jewish community center in Argentina that was blamed on Tehran and Hezbollah. It could be days or weeks before the full impact of the U.S. strikes on Iran's nuclear sites is known. But experts have long warned that even joint U.S. and Israeli strikes would only delay Iran's ability to develop a weapon, not eliminate it. That's because Iran has dispersed its program across the country to several sites, including hardened, underground facilities. Iran would probably struggle to repair or reconstitute its nuclear program while Israeli and U.S. warplanes are circling overhead. But it could still decide to fully end its cooperation with the International Atomic Energy Agency and abandon the Nuclear Nonproliferation Treaty. North Korea announced its withdrawal from the treaty in 2003 and tested a nuclear weapon three years later, but it had the freedom to develop its program without punishing airstrikes. Iran contends that its program is peaceful, though it is the only non-nuclear-armed state to enrich uranium up to 60%, a short, technical step away from weapons-grade levels of 90%. U.S. intelligence agencies and the IAEA assess Iran hasn't had an organized military nuclear program since 2003. Israel is widely believed to be the only nuclear-armed state in the Middle East but does not acknowledge having such weapons. Krauss and Gambrell write for the Associated Press.

The Hill

2 hours ago

• The Hill

Food and Drug Administration staff cuts may hinder US biomedical innovation

President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.